• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

KRAS

Pfizer
Biotech

Pfizer trims obesity pipeline, axes phase 2 lung disease asset

Pfizer has axed a pulmonary arterial hypertension program, dealing a setback to a long-running effort to treat the lung disease by targeting BMP9.
Nick Paul Taylor Nov 3, 2026 8:02am
ESMO 2026

From RAS rivalry to leaked readouts, ESMO brought the data drama

Oct 27, 2026 8:00am
Incyte

ESMO: Incyte claims ‘neck and neck’ KRAS G12D race with RevMed

Oct 26, 2026 9:45am
Roche ESMO 2026

ESMO: Roche touts ‘convincing’ KRAS data after phase 3 win

Oct 25, 2026 11:30am
Photo of a person celebrating at the top of the mountain while the sun setsrises

Verastem CEO says RAS drug 'set new benchmark' for tricky cancer

Oct 14, 2026 10:27am
Merck booth at AACR 2026

Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D

Sep 28, 2026 7:59am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings